寡转移性非小细胞肺癌的根治性治疗:是否已到临床应用时机?
本文综述寡转移性非小细胞肺癌(NSCLC)局部消融治疗(LAT)的证据。回顾性研究提示LAT可带来良好局部控制并改善无进展生存;首项局部巩固治疗对比维持治疗或观察的随机II期试验显示中位无进展生存期显著改善并延迟新病灶出现,提示巩固治疗可能具有全身性获益,但需未来试验进一步确认。
要点
- 寡转移性NSCLC被视为介于真正局限性疾病与广泛转移性肿瘤之间的中间状态。
- 回顾性研究提示局部消融治疗可带来良好局部控制并改善无进展生存。
- 首项随机II期试验显示局部巩固治疗较维持治疗或观察中位无进展生存期显著改善并延迟新病灶出现。
核心结论
- 首项随机II期试验显示局部巩固治疗较维持治疗或观察显著改善中位无进展生存期并延迟新病灶出现,提示巩固治疗可能具有全身性扩展获益。
- 作者指出需未来更多试验进一步确认该证据,才能最终考虑将局部治疗技术与近期获批用于NSCLC的新型全身药物(如免疫检查点抑制剂)联合。
研究设计与样本
- 本文为关于寡转移性NSCLC根治性治疗的综述,涉及回顾性研究及首项随机II期试验。
- 随机II期试验比较局部巩固治疗与维持治疗或观察。
主要发现
- 回顾性研究提示对寡转移性疾病使用局部消融治疗可提供良好局部控制并改善无进展生存。
- 首项随机II期试验显示局部治疗使中位无进展生存期获得显著改善,并延迟新病灶出现。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者指出需未来更多试验进一步确认该证据,才能最终考虑将局部治疗技术与新型全身药物联合。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Oligometastatic non-small cell lung cancer (NSCLC), defined as a disease with low metastatic burden and limited organ involvement, is conceived as an intermediate condition between a truly localised disease and a widely metastatic tumour. Traditionally, local ablative therapies (LATs), such as surgery and radiotherapy, have been limited to symptoms' palliation in advanced NSCLC. Several retrospective studies suggest that using local ablative therapy for oligometastatic disease could offer good local control of the disease and improvement in terms of progression-free survival. The first randomised study of local consolidative therapy versus maintenance therapy or observation in oligometastatic NSCLC has been recently published. The results of this phase II trial showed an impressive improvement in median progression-free survival with local therapy and a delay in the appearance of new lesions, suggesting a systemically extended benefit of consolidation therapies. Nevertheless, further confirmation of this evidence with additional future trials is needed to definitively consider the combination of local treatment techniques with novel systemic agents recently approved for NSCLC therapy, such as immune checkpoint inhibitors.
引用
- Brighenti M, Petrelli F, Barni S, et al. Radical treatment of oligometastatic non-small cell lung cancer: Ready for prime time? Eur J Cancer. 2017. PMID: 28494405. doi:10.1016/j.ejca.2017.04.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。